Reported May 23,
2003
Help for Adult ADHD
SAN FRANCISCO (Ivanhoe
Newswire) -- Nearly 70 percent
of children diagnosed with
attention-deficit-hyperactivity
disorder may still experience
symptoms as adults. Now, experts
say medication can help.
Researchers from the
University of North Carolina at
Chapel Hill studied more than
240 adults who suffered from
ADHD. All participants had a
history of the disorder before
age 7 and many were not properly
diagnosed until they became
adults. The patients were given
daily doses of 20 milligrams, 40
milligrams or 60 milligrams of
amphetamine medication for four
weeks.
Results of the study show
adults with ADHD who are treated
with amphetamines experience
fewer symptoms associated with
their disorder. The patients
rating scores, which are used to
measure the effectiveness of a
drug, were significantly lower
after being treated with
amphetamines. Reduction in
rating scores indicates improved
symptoms.
Patients who took the lowest
dose of medication saw a
40-percent mean score decrease
in symptoms. Those on the median
dose had their symptoms drop by
41 percent, and participants on
the highest dose saw a
44-percent decline in symptoms.
Most side effects associated
with taking the drugs were mild
and occurred early in the study.
The most frequently reported
adverse effects were dry mouth,
loss of appetite, insomnia and
headache. These problems
improved over time.
Nearly 8 million American
adults have ADHD. The disorder
causes inattention,
hyperactivity and impulsivity.
ADHD can often lead to
psychological, work-related and
social problems.
Richard H. Weisler, M.D.,
from the University of North
Carolinas School of Medicine,
says, This medication can
significantly improve adults
ADHD symptoms and, subsequently,
their ability to work,
socialize, and be more
productive in everyday
activities.
This article was reported by
Ivanhoe.com, who offers Medical
Alerts by e-mail every day of
the week. To subscribe, go to:
http://www.ivanhoe.com/newsalert/.
SOURCE: American Psychiatric
Association Annual Meeting, San
Francisco, May 17-22, 2003